市場調查報告書

COVID-19臨床試驗的全球市場:2020-2027年

COVID-19 Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Product (Therapeutics, Drugs), By Region, And Segment Forecasts, 2020 - 2027

出版商 Grand View Research, Inc. 商品編碼 952702
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
COVID-19臨床試驗的全球市場:2020-2027年 COVID-19 Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Product (Therapeutics, Drugs), By Region, And Segment Forecasts, 2020 - 2027
出版日期: 2020年07月30日內容資訊: 英文 120 Pages
簡介

全球新型冠狀病毒感染疾病 (COVID-19) 臨床試驗的市場在預測期間內預計將以9.5%的年複合成長率推移,到2027年成長到99億美元的規模。許多製藥公司,生物技術公司和研究機構目前正在研究開發針對冠狀病毒的有效治療劑。已為COVID-19開發了661種化合物,其中292種是藥物,173種是疫苗,196種是抗病毒藥。

本報告提供全球新型冠狀病毒感染疾病 (COVID-19) 臨床試驗的市場調查,彙整市場定義和概要,價值鏈,COVID-19以及其他的市場影響因素分析,市場規模的轉變·預測,酒精濃度·通路·地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊。

第1章 調查手法·調查範圍

第2章 摘要整理

第3章 市場可變因素·趨勢·展望

  • 市場展望
  • 普及率·成長率預測
  • 產品平台分析:不同階段
  • SARS·MERS的專利
  • COVID-19:對醫療保健產業的影響
  • COVID-19:聯盟契約
  • COVID-19:收購分析
  • 聯合臨床試驗
  • 虛擬臨床試驗
  • 技術引進的增加
  • 市場動態
  • 市場分析工具

第4章 市場預測·趨勢分析:不同階段

  • 階段I
  • 階段II
  • 階段III
  • 階段IV
  • 其他

第5章 市場預測·趨勢分析:各產品

  • 治療藥
  • 疫苗

第6章 市場預測·趨勢分析:地區·各主要國家

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
  • 中東·非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第7章 競爭分析

  • 主要醫藥品·生物醫藥品企業的簡介
    • Moderna
    • GlaxoSmithKline
    • Pfizer
    • Johnson & Johnson
    • Gilead Sciences Inc.
    • Inovio Pharmaceuticals
    • Abbvie
    • BioNTech SE
    • Novavax
    • Takeda
  • 主要CRO的簡介
    • NOVOTECH
    • ICON Plc
    • IQVIA
    • Bioclinica
    • Medidata Solutions
    • PRA health Sciences
    • Covance
    • Parexel
    • Quanticate
目錄
Product Code: GVR-4-68038-907-4

Market Growth & Trends

The global COVID-19 clinical trials market size is expected to reach USD 9.9 billion by 2027, registering a CAGR of 9.5% during the forecast period, according to a new report by Grand View Research, Inc. An increasing number of deaths due to coronavirus is creating a need to develop effective treatments, thereby boosting the market growth. Also, the underlying economic profits for first movers are encouraging pharmaceutical players to invest in clinical trial studies for COVID-19.

The current pandemic poses an acute health risk to the entire population. A key to successfully fighting COVID-19 lies in clinical research. At present, almost all the major research-based pharmaceutical companies, many other biotechnology and pharmaceutical companies, as well as research institutes are engaged in a race to develop an effective treatment against coronavirus. There are currently 661 unique compounds in development against COVID-19, of which 292 are drugs, 173 are vaccines and 196 are antivirals.

The regulators in the U.S. and Europe also offer various options for action and procedural facilitation to enable faster access to effective vaccines and drugs to combat the pandemic. In March 2020, the Solidarity Trial-an international clinical trial by the World Health Organization (WHO)-was launched to find effective treatment against COVID-19. In May 2020, WHO also announced an international alliance for developing various candidate vaccines to stop the spread of coronavirus disease, calling this effort the Solidarity trial for vaccines.

The current scenario across the globe and the need to come up with treatment options has also led to the fast-track of clinical trials. Hence, in March 2020, the Food and Drug Administration (FDA) launched a Coronavirus Treatment Acceleration Program (CTAP) for the likely therapies to accelerate the development of the treatment for the pandemic caused by a coronavirus. Recently in May 2020, the U.S. FDA granted fast track title to Moderna's mRNA vaccine candidate, mRNA-1273, to protect against COVID-19.

Report Highlights:

  • Phase II COVID-19 clinical trials dominated the market with a share of 35.0% in 2020. This is attributed to the maximum number of products currently in development.
  • Vaccines segment accounted for the largest share of 77.1% in 2020 owing to the increasing investments towards it.
  • Europe held 46.8% of the market share in 2020. Favorable government initiatives such as the UK's "ACCORD" clinical trial program are contributing to market growth.
  • The Asia Pacific region is projected to witness the fastest CAGR of 11.8% during the forecast period as the increasing number of biotechnology firms are looking at the region for their COVID-19 trials to take advantage of the large patient pool and fast-track procedures.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Phase
    • 1.1.2. Product
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1: Understanding the market dynamics
    • 1.9.2. Objective 2: Understanding the market estimates and forecasts
    • 1.9.3. Objective 3: Understanding the attributes such as strategy framework, competitor categorization
    • 1.9.4. Objective 4: Understanding the key product and application scopes to conclude on the market size

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. COVID-19 Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Product Pipeline Analysis, by Phase
    • 3.3.1. Therapeutics in development
    • 3.3.2. Vaccines in development
  • 3.4. Patents of SARS and MERS with possible relevance to COVID-19
    • 3.4.1. Patents & potential drug candidates related to key protein targets
    • 3.4.2. Patents of existing drugs with potential applications for COVID-19
  • 3.5. COVID-19 impact on healthcare industry
    • 3.5.1. Disrupted clinical trials, by phase
      • 3.5.1.1. Companies with phase 1 trial disruption
      • 3.5.1.2. Companies with phase 2 trial disruption
      • 3.5.1.3. Companies with phase 3 trial disruption
    • 3.5.2. Fast track of clinical trials (Will add more content in this)
      • 3.5.2.1. FDA initiative -CTPA
      • 3.5.2.2. UK initiative -ACCORD
      • 3.5.2.3. Asia Pacific initiative - DCGI
      • 3.5.2.4. University of Pittsburgh School of Medicine-UPMC
  • 3.6. COVID-19 Collaboration Deals
    • 3.6.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    • 3.6.2. Company-University Collaborations (Licensing / Partnering) Analysis
  • 3.7. COVID-19 Acquisition Analysis
  • 3.8. Solidarity Clinical Trials
    • 3.8.1. Participation in solidarity trials
    • 3.8.2. Solidarity clinical trial for vaccines
    • 3.8.3. Solidarity II
  • 3.9. Virtual clinical trials
    • 3.9.1. In-home clinical services
  • 3.10. Increase in the adoption of technology
    • 3.10.1. The rise of digital revolution
    • 3.10.2. Emerging role of wearable in clinical trials
  • 3.11. Market Dynamics
    • 3.11.1. Market Driver Analysis
      • 3.11.1.1. Increasing number of deaths due to rapid spread of coronavirus
      • 3.11.1.2. Increasing funding for COVID-19 research (public & private)
      • 3.11.1.3. Disruption in the global supply chain of medicines and other necessary products
      • 3.11.1.4. Economic loss leading to Fastrack of COVID 19 clinical trials
    • 3.11.2. Market Restraint Analysis
      • 3.11.2.1. Access to patient population
      • 3.11.2.2. Timeframe for research
  • 3.12. COVID-19 Clinical Trials: Market Analysis Tools
    • 3.12.1. Industry Analysis - Porter's
    • 3.12.2. PESTEL Analysis

Chapter 4. COVID-19 Clinical Trials Market: Segment Analysis, by Phase, 2016 - 2027 (USD Million)

  • 4.1. Segment Dashboard
  • 4.2. Phase Market Share Analysis, 2020 & 2027
  • 4.3. COVID-19 Clinical Trials Market, by Phase, 2016 to 2027
  • 4.4. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 4.4.1. Phase I
    • 4.4.2. Phase II
    • 4.4.3. Phase III
    • 4.4.4. Phase IV
    • 4.4.5. Others

Chapter 5. COVID-19 Clinical Trials Market: Segment Analysis, By Product, 2016 - 2027 (USD Million)

  • 5.1. Segment Dashboard
  • 5.2. Product Market Share Analysis, 2020 & 2027
  • 5.3. Global COVID-19 Clinical Trials Market, by Product, 2016 to 2027
  • 5.4. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 5.4.1. Therapeutics
    • 5.4.2. Vaccines

Chapter 6. COVID-19 Clinical Trials Market: Segment Analysis, By Phase, 2016 - 2027 (USD Million)

  • 6.1. Regional Market Dashboard
  • 6.2. Market Size, & Forecasts, and Trend Analysis, 2016 to 2027:
  • 6.3. North America
    • 6.3.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 6.3.2. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
    • 6.3.3. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.3.4. The U.S.
      • 6.3.4.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.3.4.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.3.5. Canada
      • 6.3.5.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.3.5.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
  • 6.4. Europe
    • 6.4.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 6.4.2. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
    • 6.4.3. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.4.4. Germany
      • 6.4.4.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.4.4.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.4.5. The U.K.
      • 6.4.5.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.4.5.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.4.6. France
      • 6.4.6.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.4.6.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.4.7. Italy
      • 6.4.7.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.4.7.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.4.8. Spain
      • 6.4.8.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.4.8.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 6.5.2. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
    • 6.5.3. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.5.4. China
      • 6.5.4.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.5.4.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.5.5. Japan
      • 6.5.5.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.5.5.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.5.6. India
      • 6.5.6.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.5.6.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.5.7. Australia
      • 6.5.7.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.5.7.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.5.8. South Korea
      • 6.5.8.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.5.8.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 6.6.2. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
    • 6.6.3. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.6.4. Brazil
      • 6.6.4.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.6.4.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.6.5. Mexico
      • 6.6.5.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.6.5.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.6.6. Argentina
      • 6.6.6.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.6.6.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.6.7. Colombia
      • 6.6.7.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.6.7.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
  • 6.7. The Middle East and Africa
    • 6.7.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 6.7.2. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
    • 6.7.3. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.7.4. South Africa
      • 6.7.4.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.7.4.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.7.5. Saudi Arabia
      • 6.7.5.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.7.5.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)
    • 6.7.6. UAE
      • 6.7.6.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
      • 6.7.6.2. Market estimates and forecast, by product, 2016 - 2027 (USD Million)

Chapter 7. Clinical Trials Market- Competitive Analysis

  • 7.1. Key pharmaceutical/biopharmaceutical companies profiled
    • 7.1.1. Moderna
      • 7.1.1.1. Company Overview
      • 7.1.1.2. Financial Performance
      • 7.1.1.3. Product Benchmarking
      • 7.1.1.4. Strategic Initiatives
    • 7.1.2. GlaxoSmithKline
      • 7.1.2.1. Company Overview
      • 7.1.2.2. Financial Performance
      • 7.1.2.3. Product Benchmarking
      • 7.1.2.4. Strategic Initiatives
    • 7.1.3. Pfizer
      • 7.1.3.1. Company Overview
      • 7.1.3.2. Financial Performance
      • 7.1.3.3. Product Benchmarking
      • 7.1.3.4. Strategic Initiatives
    • 7.1.4. Johnson & Johnson
      • 7.1.4.1. Company Overview
      • 7.1.4.2. Financial Performance
      • 7.1.4.3. Product Benchmarking
      • 7.1.4.4. Strategic Initiatives
    • 7.1.5. Gilead Sciences Inc.
      • 7.1.5.1. Company Overview
      • 7.1.5.2. Financial Performance
      • 7.1.5.3. Product Benchmarking
      • 7.1.5.4. Strategic Initiatives
    • 7.1.6. Inovio Pharmaceuticals
      • 7.1.6.1. Company Overview
      • 7.1.6.2. Financial Performance
      • 7.1.6.3. Product Benchmarking
      • 7.1.6.4. Strategic Initiatives
    • 7.1.7. Abbvie
      • 7.1.7.1. Company Overview
      • 7.1.7.2. Financial Performance
      • 7.1.7.3. Product Benchmarking
      • 7.1.7.4. Strategic Initiatives
    • 7.1.8. BioNTech SE
      • 7.1.8.1. Company Overview
      • 7.1.8.2. Financial Performance
      • 7.1.8.3. Product Benchmarking
      • 7.1.8.4. Strategic Initiatives
    • 7.1.9. Novavax
      • 7.1.9.1. Company Overview
      • 7.1.9.2. Financial Performance
      • 7.1.9.3. Product Benchmarking
      • 7.1.9.4. Strategic Initiatives
    • 7.1.10. Takeda
      • 7.1.10.1. Company Overview
      • 7.1.10.2. Financial Performance
      • 7.1.10.3. Product Benchmarking
      • 7.1.10.4. Strategic Initiatives
  • 7.2. Key CRO's profiled
    • 7.2.1. NOVOTECH
      • 7.2.1.1. Company Overview
      • 7.2.1.2. Financial Performance
      • 7.2.1.3. Product Benchmarking
      • 7.2.1.4. Strategic Initiatives
    • 7.2.2. ICON Plc
      • 7.2.2.1. Company Overview
      • 7.2.2.2. Financial Performance
      • 7.2.2.3. Product Benchmarking
      • 7.2.2.4. Strategic Initiatives
    • 7.2.3. IQVIA
      • 7.2.3.1. Company Overview
      • 7.2.3.2. Financial Performance
      • 7.2.3.3. Product Benchmarking
      • 7.2.3.4. Strategic Initiatives
    • 7.2.4. Bioclinica
      • 7.2.4.1. Company Overview
      • 7.2.4.2. Financial Performance
      • 7.2.4.3. Product Benchmarking
      • 7.2.4.4. Strategic Initiatives
    • 7.2.5. Medidata Solutions
      • 7.2.5.1. Company Overview
      • 7.2.5.2. Financial Performance
      • 7.2.5.3. Product Benchmarking
      • 7.2.5.4. Strategic Initiatives
    • 7.2.6. PRA health Sciences
      • 7.2.6.1. Company Overview
      • 7.2.6.2. Financial Performance
      • 7.2.6.3. Product Benchmarking
      • 7.2.6.4. Strategic Initiatives
    • 7.2.7. Covance
      • 7.2.7.1. Company Overview
      • 7.2.7.2. Financial Performance
      • 7.2.7.3. Product Benchmarking
      • 7.2.7.4. Strategic Initiatives
    • 7.2.8. Parexel
      • 7.2.8.1. Company Overview
      • 7.2.8.2. Financial Performance
      • 7.2.8.3. Product Benchmarking
      • 7.2.8.4. Strategic Initiatives
    • 7.2.9. Quanticate
      • 7.2.9.1. Company Overview
      • 7.2.9.2. Financial Performance
      • 7.2.9.3. Product Benchmarking
      • 7.2.9.4. Strategic Initiatives
    • 7.2.10. Pharmaceutical Product Development
      • 7.2.10.1. Company Overview
      • 7.2.10.2. Financial Performance
      • 7.2.10.3. Product Benchmarking
      • 7.2.10.4. Strategic Initiatives 

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Clinical Trials Market, By Region 2016 - 2027 (USD Million)
  • Table 4 Global COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 5 Global COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 6 North America COVID-19 Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
  • Table 7 North America COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 8 North America COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 9 The U.S. COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 10 The U.S. COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 11 Canada COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 12 Canada COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 13 Europe COVID-19 Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
  • Table 14 Europe COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 15 Europe COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 16 The U.K. COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 17 The U.K. COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 18 Germany COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 19 Germany COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 20 France COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 21 France COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 22 Italy COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 23 Italy COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 24 Spain COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 25 Spain COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 26 Asia Pacific COVID-19 Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
  • Table 27 Asia Pacific COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 28 Asia Pacific COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 29 India COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 30 India COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 31 Japan COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 32 Japan COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 33 China COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 34 China COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 35 Australia COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 36 Australia COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 37 South Korea COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 38 South Korea COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 39 Latin America COVID-19 Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
  • Table 40 Latin America COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 41 Latin America COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 42 Brazil COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 43 Brazil COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 44 Mexico COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 45 Mexico COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 46 Argentina COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 47 Argentina COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 48 Colombia COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 49 Colombia COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 50 MEA COVID-19 Clinical Trials Market, By Country, 2016 - 2027 (USD Million)
  • Table 51 MEA COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 52 MEA COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 53 MEA Clinical Trials Market, By Indication, 2016 - 2027 (USD Million)
  • Table 54 South Africa COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 55 South Africa COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 56 Saudi Arabia COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 57 Saudi Arabia COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)
  • Table 58 UAE COVID-19 Clinical Trials Market, By Phase, 2016 - 2027 (USD Million)
  • Table 59 UAE COVID-19 Clinical Trials Market, By Product, 2016 - 2027 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 COVID-19 Clinical Trials: Market snapshot
  • Fig. 9 COVID-19 Clinical Trials: Market segmentation
  • Fig. 10 COVID-19 Clinical Trials Market Strategy framework
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 COVID-19 clinical trials market driver impact
  • Fig. 14 COVID-19 clinical trials market restraint impact
  • Fig. 15 COVID-19 clinical trials market porter's five forces analysis
  • Fig. 16 COVID-19 clinical trials market PESTEL analysis
  • Fig. 17 COVID-19 clinical trials market segment dashboard
  • Fig. 18 COVID-19 Clinical Trials Market: Phase movement Analysis
  • Fig. 19 Phase I estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 20 Phase II estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 21 Phase III estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 22 Phase IV estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 23 Others estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 24 COVID-19 clinical trials market Segment dashboard
  • Fig. 25 COVID-19 clinical trials market: Product Movement analysis
  • Fig. 26 Therapeutics market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 27 Vaccines market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 28 Global COVID-19 clinical trials market: Regional movement analysis
  • Fig. 29 Global COVID-19 clinical trials market: Regional outlook and key takeaways
  • Fig. 30 Global COVID-19 market share, by region
  • Fig. 31 North America market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 32 The U.S. market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 33 Canada market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 34 Europe market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 35 The U.K. market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 36 Germany market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 37 France market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 38 Italy market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 39 Spain market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 40 Asia Pacific market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 41 China market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 42 Japan market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 43 India market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 44 Australia market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 45 South Korea market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 46 Latin America market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 47 Brazil market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 48 Mexico market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 49 Argentina market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 50 Colombia market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 51 The Middle East and Africa. market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 52 South Africa market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 53 Saudi Arabia market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 54 UAE market estimates and forecast, 2016 - 2027 (USD Million)